162358-07-8Relevant articles and documents
Development of novel PP2A activators for use in the treatment of acute myeloid leukaemia
Toop, Hamish D.,Dun, Matthew D.,Ross, Bryony K.,Flanagan, Hayley M.,Verrills, Nicole M.,Morris, Jonathan C.
, p. 4605 - 4616 (2016/06/09)
AAL(S), the chiral deoxy analog of the FDA approved drug FTY720, has been shown to inhibit proliferation and apoptosis in several cancer cell lines. It has been suggested that it does this by activating protein phosphatase 2A (PP2A). Here we report the synthesis of new cytotoxic analogs of AAL(S) and the evaluation of their cytotoxicity in two myeloid cell lines, one of which is sensitive to PP2A activation. We show that these analogs activate PP2A in these cells supporting the suggested mechanism for their cytotoxic properties. Our findings identify key structural motifs required for anti-cancer effects.
FINGOLIMOD HYDROCHLORIDE PROCESS
-
, (2015/07/07)
A process for preparation of diethyl 2-acetamido-2-(4-octyl phenyl)ethyl malonate (III), a key intermediate of fingolimod hydrochloride comprising reaction of 2-(4- octylphenyl)ethyl iodide (IV) with diethyl acetamido malonate in presence of a base and an iodinating agent and in an organic solvent. The compound of formula (III) thus obtained provided fingolimod hydrochloride (la) having associated impurities below the regulatory limits.
Iron-catalyzed cross-coupling reactions. A scalable synthesis of the immunosuppressive agent FTY720
Seidel, Guenter,Laurich, Daniel,Fuerstner, Alois
, p. 3950 - 3952 (2007/10/03)
A chemo- and regioselective cross-coupling reaction of the functionalized aryl triflate 5 with octylmagnesium bromide catalyzed by cheap, nontoxic, and environmentally benign Fe(acac)3 sets the basis for a practical and scaleable synthesis of the octylbenzene derivative 6, which serves as a key building block for the preparation of FTY720 (1). This 2-amino-1,3-propanediol derivative shows highly promising immunosuppressive properties and is currently in human clinical phase III trials.